A note on post-marketing safety study design to characterise time-dependent adverse events

被引:1
|
作者
Narukawa, Mamoru
Yafune, Akifumi
机构
[1] Kitasato Univ, Grad Sch, Div Pharmaceut Med, Tokyo, Japan
[2] Clin Sendagaya, Tokyo, Japan
关键词
safety study design; time-dependent adverse events; Weibull model;
D O I
10.1002/pds.1472
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose To investigate a suitable post-marketing safety study design, that is number of patients and duration of exposure, to well characterise adverse events (AEs) profiles under limited resources, fixed patient-months. Methods A simulation study is conducted to investigate a suitable study design that can appropriately characterise the shape of the hazard function of AEs using the Weibull model. The reliability of the estimates is evaluated by referring their bias and mean squared error (MSE). Results In general, patients should be followed for a longer period even if the number of patients is relatively small for characterising delayed AEs. Patients' drop-out affects the estimation and deteriorates its reliability. For AEs that are likely to occur soon after the exposure, a study with relatively shorter duration and large number of patients is preferable. Conclusions It is important to evaluate statistically the appropriate study design in planning a safety study so that a good estimate of the hazard function would be obtained. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:1146 / 1152
页数:7
相关论文
共 50 条
  • [1] Post-Marketing Survey of Adverse Events Following Ocriplasmin
    Shah, Sumit P.
    Jeng-Miller, Karen W.
    Fine, Howard F.
    Wheatley, H. Matthew
    Roth, Daniel B.
    Prenner, Jonathan L.
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2016, 47 (02): : 156 - 160
  • [2] POST-MARKETING SAFETY STUDIES Three design aspects for high quality post-marketing cohort studies
    Fralick, Michael
    Kesselheim, Aaron S.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
  • [3] Determining sample size for post-marketing surveillance of rare adverse events
    Wang, Jianmin
    Sherrill, Beth
    Irish, William
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S119 - S120
  • [4] Decision support methods for the detection of adverse events in post-marketing data
    Hauben, M.
    Bate, A.
    [J]. DRUG DISCOVERY TODAY, 2009, 14 (7-8) : 343 - 357
  • [5] Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004
    Nakayama, Tetsuo
    Onoda, Kazumasa
    [J]. VACCINE, 2007, 25 (03) : 570 - 576
  • [6] Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance
    Kanbayashi, Yuko
    Kojima, Asuka
    Wakabayashi, Haruka
    Shimizu, Tadashi
    Uchida, Mayako
    [J]. ONCOLOGY, 2023, : 799 - 807
  • [7] Safety of Sublingual Immunotherapy: A Secondary Analysis of Post-marketing Adverse Events Reports Using a Japanese Public Database
    Kaneda, Yudai
    Kaneda, Uiri
    Namba, Mira
    Tanimoto, Tetsuya
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [8] Respiratory adverse events and outcomes with salmeterol-fluticasone: Post-marketing experience
    Almenoff, June
    Clines, Dawn
    Yancey, Steve
    Yuen, Nancy
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S171 - S172
  • [9] The safety of risperidone: a post-marketing study on 7684 patients
    Mackay, FJ
    Wilton, LV
    Pearce, GL
    Freemantle, SN
    Mann, RD
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1998, 13 (06) : 413 - 418
  • [10] Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
    Wakabayashi, Tomohito
    Nakatsuji, Takahiro
    Kambara, Hiroko
    Niinomi, Iku
    Oyama, Saki
    Inada, Ayaka
    Ueno, Sayaka
    Uchida, Mayako
    Iwanaga, Kazunori
    Iida, Tatsuya
    Hosohata, Keiko
    [J]. CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2022, 17 (02) : 144 - 148